Fulcrum Therapeutics Stock Performance
| FULC Stock | USD 3.15 0.13 4.30% |
The firm shows a Beta (market volatility) of 1.17, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Fulcrum Therapeutics will likely underperform. At this point, Fulcrum Therapeutics has a negative expected return of -0.58%. Please make sure to confirm Fulcrum Therapeutics' treynor ratio, accumulation distribution, price action indicator, as well as the relationship between the potential upside and day median price , to decide if Fulcrum Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Fulcrum Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's essential indicators remain rather sound which may send shares a bit higher in April 2025. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders. ...more
Actual Historical Performance (%)
One Day Return 4.3 | Five Day Return 0.96 | Year To Date Return (34.92) | Ten Year Return (76.67) | All Time Return (76.67) |
1 | Acquisition by Oltmans Curtis Gale of 225000 shares of Fulcrum Therapeutics at 4.16 subject to Rule 16b-3 | 01/24/2025 |
2 | Fulcrum Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences ... | 02/06/2025 |
3 | Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 | 02/07/2025 |
4 | Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call and Webcast on Tuesday, February 25, 2025, at 800 a.m. ET | 02/18/2025 |
5 | Disposition of 3410 shares by Tourangeau Greg of Fulcrum Therapeutics at 16.87 subject to Rule 16b-3 | 02/20/2025 |
6 | Fulcrum Therapeutics Announces Recent Business Highlights and Financial Resultsfor Fourth Quarter and Full Year 2024 | 02/25/2025 |
7 | Fulcrum Therapeutics, Inc. Q4 2024 Earnings Call Transcript | 02/26/2025 |
8 | Investors who lost money on Fulcrum Therapeutics, Inc. should contact Levi Korsinsky about an ongoing investigation - FULC - ACCESS Newswire | 03/06/2025 |
9 | Acquisition by Mel Hayes of 137000 shares of Fulcrum Therapeutics subject to Rule 16b-3 | 03/14/2025 |
| Begin Period Cash Flow | 26.7 M |
Fulcrum |
Fulcrum Therapeutics Relative Risk vs. Return Landscape
If you would invest 468.00 in Fulcrum Therapeutics on December 23, 2024 and sell it today you would lose (153.00) from holding Fulcrum Therapeutics or give up 32.69% of portfolio value over 90 days. Fulcrum Therapeutics is currently does not generate positive expected returns and assumes 3.5536% risk (volatility on return distribution) over the 90 days horizon. In different words, 31% of stocks are less volatile than Fulcrum, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Fulcrum Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Fulcrum Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Fulcrum Therapeutics, and traders can use it to determine the average amount a Fulcrum Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1643
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | FULC |
Estimated Market Risk
| 3.55 actual daily | 31 69% of assets are more volatile |
Expected Return
| -0.58 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.16 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Fulcrum Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Fulcrum Therapeutics by adding Fulcrum Therapeutics to a well-diversified portfolio.
Fulcrum Therapeutics Fundamentals Growth
Fulcrum Stock prices reflect investors' perceptions of the future prospects and financial health of Fulcrum Therapeutics, and Fulcrum Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Fulcrum Stock performance.
| Return On Equity | -0.0407 | ||||
| Return On Asset | -0.0478 | ||||
| Profit Margin | (0.12) % | ||||
| Operating Margin | (0.25) % | ||||
| Current Valuation | (61.82 M) | ||||
| Shares Outstanding | 53.98 M | ||||
| Price To Earning | (1.99) X | ||||
| Price To Book | 0.70 X | ||||
| Price To Sales | 2.13 X | ||||
| Revenue | 80 M | ||||
| Gross Profit | 16.61 M | ||||
| EBITDA | (18.24 M) | ||||
| Net Income | (9.72 M) | ||||
| Cash And Equivalents | 221.79 M | ||||
| Cash Per Share | 4.26 X | ||||
| Total Debt | 17.68 M | ||||
| Debt To Equity | 0.06 % | ||||
| Current Ratio | 15.49 X | ||||
| Book Value Per Share | 4.50 X | ||||
| Cash Flow From Operations | (2.22 M) | ||||
| Earnings Per Share | (0.16) X | ||||
| Market Capitalization | 170.03 M | ||||
| Total Asset | 260.72 M | ||||
| Retained Earnings | (519.4 M) | ||||
| Working Capital | 238.88 M | ||||
| Current Asset | 22.54 M | ||||
| Current Liabilities | 3.5 M | ||||
About Fulcrum Therapeutics Performance
By analyzing Fulcrum Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Fulcrum Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Fulcrum Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Fulcrum Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (148.15) | (140.74) | |
| Return On Tangible Assets | (0.34) | (0.36) | |
| Return On Capital Employed | (0.41) | (0.43) | |
| Return On Assets | (0.34) | (0.36) | |
| Return On Equity | (0.37) | (0.39) |
Things to note about Fulcrum Therapeutics performance evaluation
Checking the ongoing alerts about Fulcrum Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Fulcrum Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Fulcrum Therapeutics generated a negative expected return over the last 90 days | |
| Fulcrum Therapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 80 M. Net Loss for the year was (9.72 M) with profit before overhead, payroll, taxes, and interest of 16.61 M. | |
| Fulcrum Therapeutics currently holds about 221.79 M in cash with (2.22 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.26, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Fulcrum Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Over 97.0% of the company shares are owned by institutional investors | |
| Latest headline from MacroaxisInsider: Acquisition by Mel Hayes of 137000 shares of Fulcrum Therapeutics subject to Rule 16b-3 |
- Analyzing Fulcrum Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Fulcrum Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Fulcrum Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Fulcrum Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Fulcrum Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Fulcrum Therapeutics' stock. These opinions can provide insight into Fulcrum Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Fulcrum Stock analysis
When running Fulcrum Therapeutics' price analysis, check to measure Fulcrum Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fulcrum Therapeutics is operating at the current time. Most of Fulcrum Therapeutics' value examination focuses on studying past and present price action to predict the probability of Fulcrum Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fulcrum Therapeutics' price. Additionally, you may evaluate how the addition of Fulcrum Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |